News
GNMSF
337.00
NaN%
--
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Barchart · 08/11 12:53
Stock Index Futures Gain With All Eyes on Key U.S. Jobs Report
Barchart · 08/07 05:26
Genmab Announces Financial Results for the First Half of 2026
Barchart · 08/06 10:02
AbbVie: Strong Q2 And New Catalysts Keep Me Bullish
Seeking Alpha · 08/03 14:05
Genmab: Multiple Late-Stage Readouts Ahead
Seeking Alpha · 07/22 15:34
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
Barchart · 07/15 05:22
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Barchart · 06/16 14:12
Major Shareholder Announcement
Barchart · 06/15 11:04
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Barchart · 06/13 11:45
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Barchart · 06/11 12:17
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Barchart · 05/29 15:35
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Barchart · 05/12 12:46
Major Shareholder Announcement
Barchart · 05/08 14:05
Genmab A/S Share Capital Reduction
Barchart · 04/17 09:56
Major Shareholder Announcement
Barchart · 04/14 09:44
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
Barchart · 04/14 05:23
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
Barchart · 04/13 08:35
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Barchart · 04/01 14:19
Major Shareholder Announcement
Barchart · 04/01 02:24
Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement
Seeking Alpha · 03/31 19:34
More
Webull provides a variety of real-time GNMSF stock news. You can receive the latest news about Genmab A/S through multiple platforms. This information may help you make smarter investment decisions.
About GNMSF
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.